应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
CAPR Capricor Therapeutics Inc
盘前交易 12-05 04:55:48 EST
25.40
-4.56
-15.22%
盘前
26.02
+0.62
+2.44%
04:55 EST
最高
30.60
最低
23.05
成交量
866.90万
今开
28.25
昨收
29.96
日振幅
25.20%
总市值
11.61亿
流通市值
10.21亿
总股本
4,572万
成交额
2.23亿
换手率
21.57%
流通股本
4,019万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读 | Capricor Therapeutics盘后大涨5.08%,因DMD疗法试验成功并启动股票发行
异动解读 · 05:44
异动解读 | Capricor Therapeutics盘后大涨5.08%,因DMD疗法试验成功并启动股票发行
Capricor股价六倍增长至40美元,因肌肉疾病细胞疗法达成晚期试验目标
美股速递 · 12-03 22:44
Capricor股价六倍增长至40美元,因肌肉疾病细胞疗法达成晚期试验目标
Capricor高管表示Deramiocel可与任何当前已批准、可用或正在临床开发的治疗药物结合使用
美股速递 · 12-03 21:37
Capricor高管表示Deramiocel可与任何当前已批准、可用或正在临床开发的治疗药物结合使用
Capricor Therapeutics高管表示公司通过圣地亚哥制造设施的预许可检查
美股速递 · 12-03 21:26
Capricor Therapeutics高管表示公司通过圣地亚哥制造设施的预许可检查
Capricor Therapeutics宣布Duchenne肌营养不良症治疗药物Deramiocel在Hope-3关键性第三阶段研究中取得积极的顶线结果
美股速递 · 12-03 20:21
Capricor Therapeutics宣布Duchenne肌营养不良症治疗药物Deramiocel在Hope-3关键性第三阶段研究中取得积极的顶线结果
Capricor Therapeutics第三季度每股收益为-0.54美元
投资观察 · 11-20
Capricor Therapeutics第三季度每股收益为-0.54美元
Capricor Therapeutics, Inc.盘中异动 股价大跌5.04%报6.73美元
市场透视 · 10-14
Capricor Therapeutics, Inc.盘中异动 股价大跌5.04%报6.73美元
Capricor Therapeutics就杜氏肌营养不良症Deramiocel项目在A类会议后发布监管进展更新
美股速递 · 09-25
Capricor Therapeutics就杜氏肌营养不良症Deramiocel项目在A类会议后发布监管进展更新
Capricor Therapeutics, Inc.8月11日成交额为1777.31万美元
市场透视 · 08-12
Capricor Therapeutics, Inc.8月11日成交额为1777.31万美元
知名疫苗监管者重返FDA,部分生物科技公司盘前下挫
老虎资讯综合 · 08-11
知名疫苗监管者重返FDA,部分生物科技公司盘前下挫
Capricor Therapeutics, Inc.8月8日成交额为2230.27万美元
市场透视 · 08-09
Capricor Therapeutics, Inc.8月8日成交额为2230.27万美元
Capricor Therapeutics, Inc.8月7日成交额为767.23万美元
市场透视 · 08-08
Capricor Therapeutics, Inc.8月7日成交额为767.23万美元
Capricor Therapeutics, Inc.8月6日成交额为555.45万美元
市场透视 · 08-07
Capricor Therapeutics, Inc.8月6日成交额为555.45万美元
Capricor Therapeutics, Inc.8月5日成交额为749.41万美元
市场透视 · 08-06
Capricor Therapeutics, Inc.8月5日成交额为749.41万美元
Capricor Therapeutics, Inc.8月4日成交额为1027.50万美元
市场透视 · 08-05
Capricor Therapeutics, Inc.8月4日成交额为1027.50万美元
Capricor Therapeutics, Inc.盘中异动 急速下跌5.07%
市场透视 · 08-01
Capricor Therapeutics, Inc.盘中异动 急速下跌5.07%
Capricor Therapeutics, Inc.7月30日成交额为4871.43万美元
市场透视 · 07-31
Capricor Therapeutics, Inc.7月30日成交额为4871.43万美元
FDA现重大人事变动!部分生物制药股飙升,REPL飙涨逾100%
智通财经网 · 07-30
FDA现重大人事变动!部分生物制药股飙升,REPL飙涨逾100%
美股异动 | FDA出现重大人事变动 部分生物制药公司股价飙升
智通财经 · 07-30
美股异动 | FDA出现重大人事变动 部分生物制药公司股价飙升
Capricor Therapeutics, Inc.盘中异动 早盘股价大跌5.08%报7.01美元
市场透视 · 07-15
Capricor Therapeutics, Inc.盘中异动 早盘股价大跌5.08%报7.01美元
加载更多
公司概况
公司名称:
Capricor Therapeutics Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
Capricor Therapeutics, Inc.在特拉华州注册成立。该公司是一家临床阶段的生物技术公司,专注于开发基于转化细胞和外泌体的疗法,用于治疗Duchenne肌营养不良症(“DMD”),这是一种罕见的导致肌肉退化和过早死亡的肌营养不良症,以及具有高度未满足的医疗需求的疾病。
发行价格:
--
{"stockData":{"symbol":"CAPR","market":"US","secType":"STK","nameCN":"Capricor Therapeutics Inc","latestPrice":25.4,"timestamp":1764882000000,"preClose":29.96,"halted":0,"volume":8668953,"hourTrading":{"tag":"盘前","latestPrice":26.02,"preClose":25.4,"latestTime":"04:55 EST","volume":2002,"amount":52246.492298000005,"timestamp":1764928509123},"delay":0,"floatShares":40185435,"shares":45718475,"eps":-1.805542,"marketStatus":"盘前交易","change":-4.56,"latestTime":"12-05 04:55:48 EST","open":28.25,"high":30.6,"low":23.05,"amount":223166608.207506,"amplitude":0.252003,"askPrice":27,"askSize":150,"bidPrice":26.01,"bidSize":70,"shortable":0,"etf":0,"ttmEps":-1.805542,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1764945000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":25.4,"preHourTrading":{"tag":"盘前","latestPrice":26.02,"preClose":25.4,"latestTime":"04:55 EST","volume":2002,"amount":52246.492298000005,"timestamp":1764928509123},"postHourTrading":{"tag":"盘后","latestPrice":26.6,"preClose":25.4,"latestTime":"19:59 EST","volume":630197,"amount":16061624.9709,"timestamp":1764896392193},"volumeRatio":0.6163237423830611,"optionData":{"bulkOrders":[{"symbol":"CAPR","call":false,"expireDate":1768539600000,"strike":"25.0","timestamp":1764861014738,"price":3.8,"volume":2453,"amount":932140,"type":"+"},{"symbol":"CAPR","call":false,"expireDate":1768539600000,"strike":"25.0","timestamp":1764861014738,"price":3.7,"volume":2452,"amount":907240,"type":"+"}]},"impliedVol":1.3812,"impliedVolPercentile":0.3133},"requestUrl":"/m/hq/s/CAPR","defaultTab":"news","newsList":[{"id":"1118988587","title":"异动解读 | Capricor Therapeutics盘后大涨5.08%,因DMD疗法试验成功并启动股票发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1118988587","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118988587?lang=zh_cn&edition=full","pubTime":"2025-12-05 05:44","pubTimestamp":1764884678,"startTime":"0","endTime":"0","summary":"Capricor Therapeutics Inc(CAPR)今日盘后股价大涨5.08%,引起了市场的广泛关注。消息面上,该公司宣布其实验性细胞疗法deramiocel在一项晚期试验中成功减缓了杜氏肌营养不良症(DMD)的发展速度。这一积极结果显著提升了投资者对该公司未来前景的信心。此外,Capricor Therapeutics还启动了股票发行计划,尽管未披露具体规模,但公司表示募集资金将用于继续开发和生产候选产品,进一步推动了股价的上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["CAPR"],"gpt_icon":0},{"id":"1156698629","title":"Capricor股价六倍增长至40美元,因肌肉疾病细胞疗法达成晚期试验目标","url":"https://stock-news.laohu8.com/highlight/detail?id=1156698629","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156698629?lang=zh_cn&edition=full","pubTime":"2025-12-03 22:44","pubTimestamp":1764773053,"startTime":"0","endTime":"0","summary":"Capricor股价六倍增长至40美元,因其肌肉疾病细胞疗法达成晚期试验目标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"325c9c18f2935f588a39c7d66a8a00d0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CAPR"],"gpt_icon":0},{"id":"1116309654","title":"Capricor高管表示Deramiocel可与任何当前已批准、可用或正在临床开发的治疗药物结合使用","url":"https://stock-news.laohu8.com/highlight/detail?id=1116309654","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116309654?lang=zh_cn&edition=full","pubTime":"2025-12-03 21:37","pubTimestamp":1764769042,"startTime":"0","endTime":"0","summary":"Capricor高管表示Deramiocel可与任何当前已批准、可用或正在临床开发的治疗药物结合使用","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPR","BK4139"],"gpt_icon":0},{"id":"1177216032","title":"Capricor Therapeutics高管表示公司通过圣地亚哥制造设施的预许可检查","url":"https://stock-news.laohu8.com/highlight/detail?id=1177216032","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177216032?lang=zh_cn&edition=full","pubTime":"2025-12-03 21:26","pubTimestamp":1764768371,"startTime":"0","endTime":"0","summary":"Capricor Therapeutics高管表示公司通过圣地亚哥制造设施的预许可检查","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPR","BK4139"],"gpt_icon":0},{"id":"1145758240","title":"Capricor Therapeutics宣布Duchenne肌营养不良症治疗药物Deramiocel在Hope-3关键性第三阶段研究中取得积极的顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1145758240","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145758240?lang=zh_cn&edition=full","pubTime":"2025-12-03 20:21","pubTimestamp":1764764470,"startTime":"0","endTime":"0","summary":"Capricor Therapeutics宣布Duchenne肌营养不良症治疗药物Deramiocel在Hope-3关键性第三阶段研究中取得积极的顶线结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"325c9c18f2935f588a39c7d66a8a00d0","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CAPR"],"gpt_icon":0},{"id":"1196171207","title":"Capricor Therapeutics第三季度每股收益为-0.54美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1196171207","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196171207?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:20","pubTimestamp":1763572836,"startTime":"0","endTime":"0","summary":"11月10日讯 - Capricor Therapeutics第三季度基本每股收益为-0.54美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CAPR"],"gpt_icon":0},{"id":"2575496265","title":"Capricor Therapeutics, Inc.盘中异动 股价大跌5.04%报6.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2575496265","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575496265?lang=zh_cn&edition=full","pubTime":"2025-10-14 00:04","pubTimestamp":1760371496,"startTime":"0","endTime":"0","summary":"北京时间2025年10月14日00时04分,Capricor Therapeutics, Inc.股票出现异动,股价大幅下跌5.04%。Capricor Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.82%。Capricor Therapeutics, Inc.公司简介:Capricor Therapeutics Inc是一家临床阶段的生物技术公司,专注于开发基于转化细胞和外泌体的治疗方法,用于治疗杜氏肌营养不良症,这是一种罕见的肌肉营养不良症,导致肌肉变性和过早死亡,以及其他医疗需求未得到满足的疾病。Deramiocel目前正在进行治疗杜氏肌营养不良症的3期临床开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014000456972b9115&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251014000456972b9115&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","CAPR","LENZ","BK4539"],"gpt_icon":0},{"id":"1192104664","title":"Capricor Therapeutics就杜氏肌营养不良症Deramiocel项目在A类会议后发布监管进展更新","url":"https://stock-news.laohu8.com/highlight/detail?id=1192104664","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192104664?lang=zh_cn&edition=full","pubTime":"2025-09-25 19:17","pubTimestamp":1758799035,"startTime":"0","endTime":"0","summary":"Capricor Therapeutics就杜氏肌营养不良症Deramiocel项目在A类会议后发布监管进展更新","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CAPR"],"gpt_icon":0},{"id":"2558692532","title":"Capricor Therapeutics, Inc.8月11日成交额为1777.31万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558692532","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558692532?lang=zh_cn&edition=full","pubTime":"2025-08-12 09:33","pubTimestamp":1754962414,"startTime":"0","endTime":"0","summary":"美东时间2025年8月11日,Capricor Therapeutics, Inc.成交额为1777.31万美元,成交额较昨日减少20.31%,当日成交量为223.13万股。Capricor Therapeutics, Inc.于2025年8月11日跌13.84%,报7.82美元,该股过去5个交易日涨1.76%,年初至今跌43.37%,过去60日涨1.89%。Deramiocel目前正在进行治疗杜氏肌营养不良症的3期临床开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812093547a6e08b8f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812093547a6e08b8f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","BK4539","LENZ","CAPR"],"gpt_icon":0},{"id":"1165295263","title":"知名疫苗监管者重返FDA,部分生物科技公司盘前下挫","url":"https://stock-news.laohu8.com/highlight/detail?id=1165295263","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165295263?lang=zh_cn&edition=full","pubTime":"2025-08-11 18:12","pubTimestamp":1754907141,"startTime":"0","endTime":"0","summary":"疫苗和免疫疗法相关股票曾出现下跌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f378b42123c17fa480658121fcaf85bc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRPT","CAPR","REPL"],"gpt_icon":0},{"id":"2558050339","title":"Capricor Therapeutics, Inc.8月8日成交额为2230.27万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2558050339","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558050339?lang=zh_cn&edition=full","pubTime":"2025-08-09 09:33","pubTimestamp":1754703215,"startTime":"0","endTime":"0","summary":"美东时间2025年8月8日,Capricor Therapeutics, Inc.成交额为2230.27万美元,成交额较昨日增加190.69%,当日成交量为248.39万股。Capricor Therapeutics, Inc.于2025年8月8日涨12.39%,报9.07美元,该股过去5个交易日涨14.81%,年初至今跌34.28%,过去60日涨24.25%。Deramiocel目前正在进行治疗杜氏肌营养不良症的3期临床开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809093340a6dbe244&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250809093340a6dbe244&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","BK4539","LENZ","CAPR"],"gpt_icon":0},{"id":"2557751504","title":"Capricor Therapeutics, Inc.8月7日成交额为767.23万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557751504","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557751504?lang=zh_cn&edition=full","pubTime":"2025-08-08 09:33","pubTimestamp":1754616795,"startTime":"0","endTime":"0","summary":"美东时间2025年8月7日,Capricor Therapeutics, Inc.成交额为767.23万美元,成交额较昨日增加38.13%,当日成交量为97.04万股。Capricor Therapeutics, Inc.于2025年8月7日涨4.26%,报8.07美元,该股过去5个交易日跌1.34%,年初至今跌41.52%,过去60日涨13.5%。Deramiocel目前正在进行治疗杜氏肌营养不良症的3期临床开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808093621a47c0611&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808093621a47c0611&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BK4007","CAPR","BK4539"],"gpt_icon":0},{"id":"2557584187","title":"Capricor Therapeutics, Inc.8月6日成交额为555.45万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557584187","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557584187?lang=zh_cn&edition=full","pubTime":"2025-08-07 09:31","pubTimestamp":1754530315,"startTime":"0","endTime":"0","summary":"美东时间2025年8月6日,Capricor Therapeutics, Inc.成交额为555.45万美元,成交额较昨日减少25.88%,当日成交量为72.22万股。Capricor Therapeutics, Inc.于2025年8月6日涨0.91%,报7.74美元,该股过去5个交易日跌5.38%,年初至今跌43.91%,过去60日涨22.08%。Deramiocel目前正在进行治疗杜氏肌营养不良症的3期临床开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807093555a6d79832&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807093555a6d79832&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CAPR","LENZ","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2557734572","title":"Capricor Therapeutics, Inc.8月5日成交额为749.41万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557734572","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557734572?lang=zh_cn&edition=full","pubTime":"2025-08-06 09:31","pubTimestamp":1754443877,"startTime":"0","endTime":"0","summary":"美东时间2025年8月5日,Capricor Therapeutics, Inc.成交额为749.41万美元,成交额较昨日减少27.06%,当日成交量为98.46万股。Capricor Therapeutics, Inc.于2025年8月5日跌0.13%,报7.67美元,该股过去5个交易日涨13.8%,年初至今跌44.42%,过去60日涨10.04%。Deramiocel目前正在进行治疗杜氏肌营养不良症的3期临床开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806093436a6d57438&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250806093436a6d57438&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","LENZ","CAPR","BK4007","BK4139"],"gpt_icon":0},{"id":"2557514356","title":"Capricor Therapeutics, Inc.8月4日成交额为1027.50万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557514356","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557514356?lang=zh_cn&edition=full","pubTime":"2025-08-05 09:30","pubTimestamp":1754357450,"startTime":"0","endTime":"0","summary":"美东时间2025年8月4日,Capricor Therapeutics, Inc.成交额为1027.50万美元,成交额较昨日减少28.49%,当日成交量为137.55万股。Capricor Therapeutics, Inc.于2025年8月4日跌2.78%,报7.68美元,该股过去5个交易日涨13.11%,年初至今跌44.35%,过去60日涨11.47%。Deramiocel目前正在进行治疗杜氏肌营养不良症的3期临床开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805093515a4756f3e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250805093515a4756f3e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4539","BK4007","CAPR","BK4139"],"gpt_icon":0},{"id":"2556814568","title":"Capricor Therapeutics, Inc.盘中异动 急速下跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2556814568","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556814568?lang=zh_cn&edition=full","pubTime":"2025-08-01 22:01","pubTimestamp":1754056897,"startTime":"0","endTime":"0","summary":"北京时间2025年08月01日22时01分,Capricor Therapeutics, Inc.股票出现波动,股价大幅下跌5.07%。Capricor Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.02%。Capricor Therapeutics, Inc.公司简介:Capricor Therapeutics Inc是一家临床阶段的生物技术公司,专注于开发基于转化细胞和外泌体的治疗方法,用于治疗杜氏肌营养不良症,这是一种罕见的肌肉营养不良症,导致肌肉变性和过早死亡,以及其他医疗需求未得到满足的疾病。Deramiocel目前正在进行治疗杜氏肌营养不良症的3期临床开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801220138a46feddd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801220138a46feddd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","CAPR","LENZ","BK4539"],"gpt_icon":0},{"id":"2555079339","title":"Capricor Therapeutics, Inc.7月30日成交额为4871.43万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555079339","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555079339?lang=zh_cn&edition=full","pubTime":"2025-07-31 09:30","pubTimestamp":1753925443,"startTime":"0","endTime":"0","summary":"美东时间2025年7月30日,Capricor Therapeutics, Inc.成交额为4871.43万美元,成交额较昨日增加257.15%,当日成交量为603.52万股。Capricor Therapeutics, Inc.于2025年7月30日涨21.36%,报8.18美元,该股过去5个交易日涨19.94%,年初至今跌40.72%,过去60日跌31.03%。Deramiocel目前正在进行治疗杜氏肌营养不良症的3期临床开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731093454a6ca8768&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250731093454a6ca8768&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","BK4539","CAPR","BK4007"],"gpt_icon":0},{"id":"1191719360","title":"FDA现重大人事变动!部分生物制药股飙升,REPL飙涨逾100%","url":"https://stock-news.laohu8.com/highlight/detail?id=1191719360","media":"智通财经网","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191719360?lang=zh_cn&edition=full","pubTime":"2025-07-30 23:31","pubTimestamp":1753889491,"startTime":"0","endTime":"0","summary":"可能有助于缓解监管压力。","market":"us","thumbnail":"https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"df3f0e1d74b88554715c54dc285ed300","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1323856.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"FDA现重大人事变动!部分生物制药股飙升,REPL飙涨逾100%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["REPL","CAPR","SRPT"],"gpt_icon":0},{"id":"2555028555","title":"美股异动 | FDA出现重大人事变动 部分生物制药公司股价飙升","url":"https://stock-news.laohu8.com/highlight/detail?id=2555028555","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555028555?lang=zh_cn&edition=full","pubTime":"2025-07-30 22:42","pubTimestamp":1753886560,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"df3f0e1d74b88554715c54dc285ed300","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE0009355771.USD","IE00B2B36J28.USD","BK4539","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4007","CAPR","REPL","BK4585","IE00BFTCPJ56.SGD","159646","LENZ","SRPT","IE0002141913.USD","BK4139"],"gpt_icon":0},{"id":"2551198940","title":"Capricor Therapeutics, Inc.盘中异动 早盘股价大跌5.08%报7.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551198940","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551198940?lang=zh_cn&edition=full","pubTime":"2025-07-15 21:55","pubTimestamp":1752587736,"startTime":"0","endTime":"0","summary":"北京时间2025年07月15日21时55分,Capricor Therapeutics, Inc.股票出现异动,股价大幅跳水5.08%。Capricor Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.47%。消息层面,截至21时55分,《H.C. Wainwright维持Capricor Therapeutics买入评级,下调目标价至24美元》资讯为影响Capricor Therapeutics, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071521553797a720d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071521553797a720d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CAPR","BK4139","LENZ","BK4539","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.capricor.com","stockEarnings":[{"period":"1week","weight":3.894},{"period":"1month","weight":3.1914},{"period":"3month","weight":2.7685},{"period":"6month","weight":0.785},{"period":"1year","weight":0.9969},{"period":"ytd","weight":0.8406}],"compareEarnings":[{"period":"1week","weight":0.0069},{"period":"1month","weight":0.0136},{"period":"3month","weight":0.0574},{"period":"6month","weight":0.1423},{"period":"1year","weight":0.1263},{"period":"ytd","weight":0.1677}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Capricor Therapeutics, Inc.在特拉华州注册成立。该公司是一家临床阶段的生物技术公司,专注于开发基于转化细胞和外泌体的疗法,用于治疗Duchenne肌营养不良症(“DMD”),这是一种罕见的导致肌肉退化和过早死亡的肌营养不良症,以及具有高度未满足的医疗需求的疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.7,"avgChangeRate":0.163345},{"month":2,"riseRate":0.5,"avgChangeRate":-0.013804},{"month":3,"riseRate":0.5,"avgChangeRate":-0.020487},{"month":4,"riseRate":0.454545,"avgChangeRate":0.454133},{"month":5,"riseRate":0.272727,"avgChangeRate":-0.152616},{"month":6,"riseRate":0.636364,"avgChangeRate":0.035159},{"month":7,"riseRate":0.363636,"avgChangeRate":0.07472},{"month":8,"riseRate":0.545455,"avgChangeRate":0.008533},{"month":9,"riseRate":0.454545,"avgChangeRate":0.348894},{"month":10,"riseRate":0.090909,"avgChangeRate":-0.099314},{"month":11,"riseRate":0.363636,"avgChangeRate":-0.0945},{"month":12,"riseRate":0.181818,"avgChangeRate":0.221801}],"exchange":"NASDAQ","name":"Capricor Therapeutics Inc","nameEN":"Capricor Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Capricor Therapeutics Inc(CAPR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Capricor Therapeutics Inc(CAPR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Capricor Therapeutics Inc,CAPR,Capricor Therapeutics Inc股票,Capricor Therapeutics Inc股票老虎,Capricor Therapeutics Inc股票老虎国际,Capricor Therapeutics Inc行情,Capricor Therapeutics Inc股票行情,Capricor Therapeutics Inc股价,Capricor Therapeutics Inc股市,Capricor Therapeutics Inc股票价格,Capricor Therapeutics Inc股票交易,Capricor Therapeutics Inc股票购买,Capricor Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Capricor Therapeutics Inc(CAPR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Capricor Therapeutics Inc(CAPR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}